LONDON: British medication group AstraZeneca on Thursday hiked its shareholder dividend citing optimism over its sturdy efficiency.
AstraZeneca “intends to extend the annualised dividend” by seven p.c to $3.10 per share, in a transfer which was “underlining the corporate’s confidence in its efficiency and money technology”, it mentioned in a press release forward of its annual normal assembly in London.
The information despatched the corporate’s share value multiple p.c larger in mid-morning offers on the British capital’s falling inventory market.
Astra board chairman Michel Demare added that the hike was “according to our progressive dividend coverage, which stays unchanged, and displays the persevering with power of AstraZeneca’s funding proposition for shareholders”.
Thursday’s information comes after the group revealed in February that web revenue virtually doubled to $6 billion final 12 months, with a powerful most cancers division serving to offset a wipeout for gross sales of Covid therapies.
Income rose three p.c to almost $46 billion in 2023 in comparison with a 12 months earlier, although gross sales of Covid therapies slumped greater than $3.7 billion. Its oncology unit’s gross sales jumped 23 p.c.
AstraZeneca final month agreed to purchase US biopharma agency Fusion for as much as $2.4 billion, in its newest growth into most cancers therapies.
Fusion is creating next-generation radiotherapy to deal with most cancers by way of exact concentrating on that minimises injury to wholesome cells. Its methodology additionally permits entry to tumours which might be laborious to succeed in utilizing normal radiation.
AstraZeneca “intends to extend the annualised dividend” by seven p.c to $3.10 per share, in a transfer which was “underlining the corporate’s confidence in its efficiency and money technology”, it mentioned in a press release forward of its annual normal assembly in London.
The information despatched the corporate’s share value multiple p.c larger in mid-morning offers on the British capital’s falling inventory market.
Astra board chairman Michel Demare added that the hike was “according to our progressive dividend coverage, which stays unchanged, and displays the persevering with power of AstraZeneca’s funding proposition for shareholders”.
Thursday’s information comes after the group revealed in February that web revenue virtually doubled to $6 billion final 12 months, with a powerful most cancers division serving to offset a wipeout for gross sales of Covid therapies.
Income rose three p.c to almost $46 billion in 2023 in comparison with a 12 months earlier, although gross sales of Covid therapies slumped greater than $3.7 billion. Its oncology unit’s gross sales jumped 23 p.c.
AstraZeneca final month agreed to purchase US biopharma agency Fusion for as much as $2.4 billion, in its newest growth into most cancers therapies.
Fusion is creating next-generation radiotherapy to deal with most cancers by way of exact concentrating on that minimises injury to wholesome cells. Its methodology additionally permits entry to tumours which might be laborious to succeed in utilizing normal radiation.
